We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · June 01, 2021

Serum NfL Levels and PML Risk in MS Patients Treated With Natalizumab

Neurology(R) neuroimmunology & neuroinflammation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Neurology(R) neuroimmunology & neuroinflammation
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
Neurol Neuroimmunol Neuroinflamm 2021 Jul 01;8(4)e1003, N Fissolo, B Pignolet, J Rio, P Vermersch, A Ruet, J deSèze, P Labauge, S Vukusic, C Papeix, L Martinez-Almoyna, A Tourbah, P Clavelou, T Moreau, J Pelletier, C Lebrun-Frenay, B Bourre, G Defer, X Montalban, D Brassat, M Comabella

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading